About the Authors
- Laurens J. Ceulemans
-
Contributed equally to this work with: Laurens J. Ceulemans, Len Verbeke
* E-mail: ceulemans.laurens@gmail.com
Affiliation Abdominal Transplant Surgery, University Hospitals Leuven, & Department of Microbiology and Immunology, KU Leuven, Belgium
- Len Verbeke
-
Contributed equally to this work with: Laurens J. Ceulemans, Len Verbeke
Affiliation Liver and Biliopancreatic Disorders, University Hospitals Leuven, KU Leuven, Belgium
- Jean-Paul Decuypere
-
Affiliation Abdominal Transplant Surgery, University Hospitals Leuven, & Department of Microbiology and Immunology, KU Leuven, Belgium
- Ricard Farré
-
Affiliation Gastro-enterology, University Hospitals Leuven, & Translational Research in Gastro-Intestinal Disorders (TARGID), KU Leuven, Belgium
- Gert De Hertogh
-
Affiliation Translational Cell and Tissue Research, University Hospitals Leuven, & Department of Imaging and Pathology, KU Leuven, Belgium
- Kaatje Lenaerts
-
Affiliation Department of Surgery, Maastricht University Medical Centre, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, the Netherlands
- Ina Jochmans
-
Affiliation Abdominal Transplant Surgery, University Hospitals Leuven, & Department of Microbiology and Immunology, KU Leuven, Belgium
- Diethard Monbaliu
-
Affiliation Abdominal Transplant Surgery, University Hospitals Leuven, & Department of Microbiology and Immunology, KU Leuven, Belgium
- Frederik Nevens
-
Affiliation Liver and Biliopancreatic Disorders, University Hospitals Leuven, KU Leuven, Belgium
- Jan Tack
-
Affiliation Gastro-enterology, University Hospitals Leuven, & Translational Research in Gastro-Intestinal Disorders (TARGID), KU Leuven, Belgium
- Wim Laleman
-
Affiliation Liver and Biliopancreatic Disorders, University Hospitals Leuven, KU Leuven, Belgium
- Jacques Pirenne
-
Affiliation Abdominal Transplant Surgery, University Hospitals Leuven, & Department of Microbiology and Immunology, KU Leuven, Belgium
Competing Interests
Frederik Nevens, co-author of this manuscript, has the following competing interest: he is an advisory board member of Intercept Pharma®. J. Pirenne received grants from commercial resources (Astellas and Roche) in support of attending scientific conferences. These grants were unrelated to the study on FXR-agonism and the presented data. There are no additional patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceptualization: LJC LV JPD RF GDH KL WL JP. Data curation: LJC LV JPD JP. Formal analysis: LJC LV JPD RF GDH KL FN JT WL JP. Funding acquisition: KL IJ DM FN JT WL JP. Investigation: LJC LV JPD RF GDH IJ DM JP. Methodology: LJC LV JPD RF GDH KL IJ DM FN JT WL JP. Project administration: LJC LV JPD RF JP. Resources: LJC LV JPD RF GDH KL IJ DM FN JT WL JP. Software: JPD RF. Supervision: FN JT WL JP. Validation: LJC LV JPD RF GDH WL JP. Visualization: LJC LV JPD RF GDH KL JP. Writing – original draft: LJC LV JPD RF KL WL JP. Writing – review & editing: LJC LV JPD RF GDH KL IJ DM FN JT WL JP.